The positive interim results from the Validation Study indicate that KidneyIntelX™ can provide a substantial improvement over standard of care in terms of predicting both Rapid Kidney Function Decline (RKFD) and progression to kidney failure (within 5 years) in patients with Type II diabetes. Although the available data is limited at this point so as not to prejudice ongoing regulatory discussions (under an accelerated pathway), the interim results are highly encouraging and confirm our
09 Jul 2019
Positive interim results from Validation Study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive interim results from Validation Study
Renalytix Plc (RENX:LON) | 25.5 -0.3 (-3.8%) | Mkt Cap: 32.2m
- Published:
09 Jul 2019 -
Author:
Jens Lindqvist -
Pages:
3
The positive interim results from the Validation Study indicate that KidneyIntelX™ can provide a substantial improvement over standard of care in terms of predicting both Rapid Kidney Function Decline (RKFD) and progression to kidney failure (within 5 years) in patients with Type II diabetes. Although the available data is limited at this point so as not to prejudice ongoing regulatory discussions (under an accelerated pathway), the interim results are highly encouraging and confirm our